Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

MEMY

252 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste | Omlaag ↓
  1. [verwijderd] 15 oktober 2007 15:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Memory Alzheimer's Drug Fails Study
    Monday October 15, 7:41 am ET
    Memory Pharmaceuticals' Alzheimer's Drug Candidate Fails in Mid-Stage Clinical Trial

    MONTVALE, N.J. (AP) -- Biotechnology company Memory Pharmaceuticals Corp. said Monday its Alzheimer's drug candidate failed a mid-stage study.
    The Phase IIa clinical trial for MEM 1003 involved 183 patients spread throughout 40 centers in the United States. The goal was an improvement in symptoms over 12 weeks.

    The group taking the therapy alone failed to show improvement and the group taking the a combination therapy with the drug candidate showed "favorable results" but they were not statistically significant. Both groups were compared with patients treated with placebo.

    The company said two patients died in the study and another three suffered serious adverse events, though none of the events were deemed treatment-related by the study investigators.

    Shares of Memory closed at $1.75 Friday.

    biz.yahoo.com/ap/071015/memory_pharma...
  3. [verwijderd] 15 oktober 2007 16:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The company said two patients died in the study and another three suffered serious adverse events, though none of the events were deemed treatment-related by the study investigators.
  4. [verwijderd] 2 november 2007 14:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease
    Friday November 2, 6:00 am ET
    - Statistically Significant Improvement on Primary and Secondary Endpoints -
    - Cognitive Benefits Support Further Development -
    - Company to Host Conference Call Today at 9:00 a.m. EDT -

    biz.yahoo.com/prnews/071102/nyf029.ht...
  5. [verwijderd] 24 december 2007 19:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Memory initiates Phase IIa trial of schizophrenia
    Monday, December 24, 2007; Posted: 09:53 AM


    *MEMORY PHARMACEUTICALS INITIATES PHASE IIA TRIAL OF MEM 3454





    Dec 24, 2007 (Datamonitor via COMTEX) -- MEMY | charts | news | PowerRating -- Memory Pharmaceuticals has initiated dosing of the first subject in a randomized, double-blind, placebo-controlled Phase IIa clinical trial of MEM 3454, the company's lead nicotinic alpha-7 receptor partial agonist, in cognitive impairment associated with schizophrenia.

    The trial is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in patients with cognitive impairment associated with schizophrenia (CIAS). The trial will enroll approximately 160 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects will be randomized to receive 5mg, 15mg or 50mg of MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effectiveness of MEM 3454 in CIAS using the Matrics Consensus Cognitive Battery (MCCB). Secondary objectives include measures of other symptoms of schizophrenia and functional capacity.

    In June 2007, Memory Pharmaceuticals expanded its nicotinic alpha-7 receptor agonist agreement with Roche to support this Phase IIa trial of MEM 3454 in CIAS. The expanded agreement provides that Roche would have to make an additional milestone payment upon completion of the Phase IIa CIAS trial to maintain its license to MEM 3454.

    Stephen Murray, chief medical officer of Memory Pharmaceuticals, said: "We currently expect to complete this trial in the fourth quarter of 2008."

    www.datamonitor.com

    Vriendelijke groet.

  6. [verwijderd] 2 mei 2008 14:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    DJ Roche Exercises Its Option To Further Develop And Commercialize Memory Pharmaceuticals´ Nicotinic Alpha-7 Agonist, MEM 3454
    DJ Memory Pharma Gets $6M Milestone Payment From Roche >MEMY

    DOW JONES NEWSWIRES

    Memory Pharmaceuticals Corp. (MEMY) said Friday it earned a $6 million milestone payment from Roche Holding AG (RHHBY), which has decided to further develop Memory Pharmaceuticals´ nicotinic alpha-7 agonist drug candidate, MEM 3454.

    The Montville, N.J. developer of therapies to treatment central nervous system conditions said the pact entitles it to future milestone and royalty payments on product sales, including a $17 million payment when it completes an ongoing Phase 2a study in cognitive impairment associated with schizophrenia.

    Memory Pharmaceuticals said it also retains an option to copromote MEM 3454 in the U.S.

    MEM 3454 showed a statistically significant effect on multiple measures of cognition in its recently completed Phase 2a study for Alzheimer´s disease, the company said.

    -Amanda Harris Falls; 201-938-5400; AskNewswires@dowjones.com



    Order free Annual Report for Genentech Incorporated

    Visit djnewswires.ar.wilink.com/?link=DNA or call 1-888-301-0513

    (END) Dow Jones Newswires

    May 02, 2008 06:45 ET (10:45 GMT)

    Copyright (c) 2008 Dow Jones & Company, Inc.

    _____________________________ Ik denk dat ie de hoogte in gaat straks...voorbeurs +30% nu.
  10. [verwijderd] 20 mei 2008 18:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste koers Verschil


    0.57 USD +0.09 (+18.75 %)
    Bid Ask
    0.56 0.57
    Bid hvh Ask hvh
    100 11800
    Volume Tijdstip
    325071 2008-05-20 18:13:24
    Slotkoers Openingskoers
    0.48 0.51
    Laagste v/d dag Hoogste v/d dag
    0.50 0.57
    _______________ Gaat weer als een raket plots,gisteren ook al +10% !
  12. [verwijderd] 20 mei 2008 18:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste koers Verschil


    0.58 USD +0.10 (+20.83 %)
    Bid Ask
    0.56 0.58
    Bid hvh Ask hvh
    4100 7900
    Volume Tijdstip
    471409 2008-05-20 18:51:07
    Slotkoers Openingskoers
    0.48 0.51
    Laagste v/d dag Hoogste v/d dag
    0.50 0.58
  20. [verwijderd] 21 mei 2008 02:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Luchthandelaar schreef:

    Laatste koers Verschil


    0.66 USD +0.18 (+37.5 %)
    Bid Ask
    0.65 0.66
    Bid hvh Ask hvh
    3900 10800
    _________________ Verkocht dayhigh !!!
    Zeverrrr, gezeverrr!!
    Nergens een aankoop te lezen, makkelijk praten achteraf.
    Je poot hier weeral de ene leugen na de andere neer!
  21. [verwijderd] 21 mei 2008 15:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Luchthandelaar schreef:

    Laatste koers Verschil


    0.66 USD +0.18 (+37.5 %)
    Bid Ask
    0.65 0.66
    Bid hvh Ask hvh
    3900 10800
    _________________ Verkocht dayhigh !!!
    Laatste koers Verschil


    0.80 USD +0.14 (+21.21 %)
    Bid Ask
    0.78 0.80
    Bid hvh Ask hvh
    200 2800
    Volume Tijdstip
    458169 2008-05-21 15:54:03
    Slotkoers Openingskoers
    0.66 0.71
    Laagste v/d dag Hoogste v/d dag
    0.69 0.81
    ______________ Werkelijk ongelooflijk,we gaan gewoon door voor de 3e dag op rij,ze gaan deze blijkbaar vlug boven de 1$ brengen.....+100% nu in enkel dagen !,ik heb ze gisteren verkocht met 30% winst jammer.
252 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.003
AB InBev 2 5.486
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.273
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.555
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.657
Aedifica 3 902
Aegon 3.258 322.677
AFC Ajax 538 7.087
Affimed NV 2 6.288
ageas 5.844 109.887
Agfa-Gevaert 14 2.048
Ahold 3.538 74.302
Air France - KLM 1.025 35.008
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.370
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.822
AMG 971 133.147
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.960
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.733
Arcelor Mittal 2.033 320.620
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.724
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.087
ASML 1.766 106.207
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 484
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.639
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392